Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 20:00 source : Investors.biomarin.com save search
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
Published: 2023-11-01 (Crawled : 20:00) - investors.biomarin.com
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -3.58%
H: 0.93%
C: -1.64%
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
Published: 2023-11-01 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -3.58%
H: 0.93%
C: -1.64%
year total growth
BioMarin to Participate in Bank of America 2023 Health Care Conference
Published: 2023-05-04 (Crawled : 20:00) - investors.biomarin.com
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: 0.36%
H: 1.41%
C: 0.88%
america conference health care
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
Published: 2023-04-26 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: -3.56%
H: 0.0%
C: 0.0%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -1.0%
H: 1.46%
C: 0.41%
total growth
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
Published: 2022-10-26 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -2.68%
H: 0.0%
C: -4.35%
kuvan growth
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
Published: 2022-09-29 (Crawled : 20:00) - investors.biomarin.com
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -0.08%
H: 2.07%
C: -0.26%
fda application license therapy
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
Published: 2022-08-03 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: 1.7%
H: 4.68%
C: 3.43%
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
Published: 2022-06-21 (Crawled : 20:00) - investors.biomarin.com
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: 0.66%
H: 6.95%
C: 4.08%
voxzogo treatment japan children granted approval injection growth achondroplasia
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
Published: 2021-07-28 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: -0.69%
H: 0.08%
C: -0.33%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: 0.03%
H: 3.57%
C: -0.3%
financial results results
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
Published: 2021-04-29 (Crawled : 20:00) - investors.biomarin.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.44%
H: 0.06%
C: -1.08%
BMRN S | $91.105 -0.44% 270K
|
Health Technology
|
| O: -0.61%
H: 0.2%
C: -2.22%
financial results results
Gainers vs Losers
| 50% | 50% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.